Paratek Pharmaceuticals (PRTK) Holder Trellus Management Company Raised Stake by $340,000; As Franklin Electric Co (FELE) Market Value Declined, Neuberger Berman Group Decreased Position

April 17, 2018 - By Ruchi Gupta

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Logo

Neuberger Berman Group Llc decreased its stake in Franklin Electric Co Inc (FELE) by 97.4% based on its latest 2017Q4 regulatory filing with the SEC. Neuberger Berman Group Llc sold 799,363 shares as the company’s stock declined 11.12% with the market. The institutional investor held 21,334 shares of the consumer durables company at the end of 2017Q4, valued at $979,000, down from 820,697 at the end of the previous reported quarter. Neuberger Berman Group Llc who had been investing in Franklin Electric Co Inc for a number of months, seems to be less bullish one the $2.00 billion market cap company. The stock increased 2.26% or $0.95 during the last trading session, reaching $42.95. About 69,537 shares traded. Franklin Electric Co., Inc. (NASDAQ:FELE) has declined 2.56% since April 17, 2017 and is downtrending. It has underperformed by 14.11% the S&P500.

Adam Usdan increased its stake in Paratek Pharmaceuticals Inc (PRTK) by 100% based on its latest 2017Q4 regulatory filing with the SEC. Trellus Management Company Llc bought 20,000 shares as the company’s stock declined 29.53% with the market. The hedge fund run by Adam Usdan held 40,000 shares of the health care company at the end of 2017Q4, valued at $716,000, up from 20,000 at the end of the previous reported quarter. Trellus Management Company Llc who had been investing in Paratek Pharmaceuticals Inc for a number of months, seems to be bullish on the $419.77M market cap company. The stock decreased 3.96% or $0.55 during the last trading session, reaching $13.35. About 413,569 shares traded. Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has declined 26.88% since April 17, 2017 and is downtrending. It has underperformed by 38.43% the S&P500.

Investors sentiment decreased to 0.91 in Q4 2017. Its down 0.63, from 1.54 in 2017Q3. It dived, as 25 investors sold PRTK shares while 29 reduced holdings. 12 funds opened positions while 37 raised stakes. 19.34 million shares or 3.86% less from 20.11 million shares in 2017Q3 were reported. Us National Bank De reported 0% of its portfolio in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). 26,600 were reported by Alliancebernstein L P. Blackrock has 1.90M shares. Community Bank & Trust Na has invested 0% of its portfolio in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Baupost Grp Ltd Liability Corporation Ma invested in 0.42% or 2.39M shares. The New York-based State Common Retirement Fund has invested 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). 10,000 are held by Harvest Management Ltd Liability Corp. D E Shaw And Communications holds 20,071 shares. Rainier Investment holds 0.58% or 76,490 shares. Landscape Mngmt Ltd Co has invested 0.02% of its portfolio in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Royal Retail Bank Of Canada has 0% invested in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) for 166 shares. 308,864 are held by General American. 125,095 are held by Susquehanna Group Inc Ltd Liability Partnership. Lazard Asset Mngmt Lc invested 0% of its portfolio in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Manufacturers Life Insurance The holds 0% or 18,705 shares.

Among 10 analysts covering Paratek Pharmaceuticals (NASDAQ:PRTK), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Paratek Pharmaceuticals had 27 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was upgraded by Zacks on Wednesday, September 2 to “Hold”. The stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has “Buy” rating given on Monday, July 17 by Cantor Fitzgerald. Robert W. Baird initiated Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) rating on Friday, May 13. Robert W. Baird has “Outperform” rating and $30 target. The firm has “Buy” rating by Cantor Fitzgerald given on Monday, June 5. Zacks downgraded the stock to “Hold” rating in Saturday, August 8 report. The stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) earned “Buy” rating by H.C. Wainwright on Tuesday, July 18. Ladenburg Thalmann maintained it with “Buy” rating and $52 target in Friday, June 17 report. The rating was reinitiated by Leerink Swann on Thursday, October 27 with “Outperform”. The stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has “Outperform” rating given on Tuesday, April 4 by Wedbush. The firm earned “Buy” rating on Friday, March 2 by H.C. Wainwright.

Among 6 analysts covering Franklin Electric (NASDAQ:FELE), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Franklin Electric had 14 analyst reports since September 30, 2015 according to SRatingsIntel. Robert W. Baird maintained the stock with “Hold” rating in Wednesday, December 13 report. Robert W. Baird maintained Franklin Electric Co., Inc. (NASDAQ:FELE) on Wednesday, April 4 with “Hold” rating. The rating was upgraded by Ladenburg Thalmann to “Neutral” on Tuesday, January 12. The rating was initiated by Alembic on Wednesday, September 30 with “Overweight”. The firm has “Hold” rating given on Wednesday, October 4 by Robert W. Baird. The stock of Franklin Electric Co., Inc. (NASDAQ:FELE) has “Buy” rating given on Tuesday, July 25 by Boenning & Scattergood. The firm has “Sell” rating by Ladenburg Thalmann given on Tuesday, December 22. The rating was maintained by Wedbush with “Neutral” on Wednesday, February 24. The firm earned “Neutral” rating on Wednesday, October 25 by Robert W. Baird. The rating was initiated by Boenning & Scattergood on Thursday, October 15 with “Neutral”.

Analysts await Franklin Electric Co., Inc. (NASDAQ:FELE) to report earnings on April, 26. They expect $0.38 earnings per share, up 15.15% or $0.05 from last year’s $0.33 per share. FELE’s profit will be $17.68M for 28.26 P/E if the $0.38 EPS becomes a reality. After $0.42 actual earnings per share reported by Franklin Electric Co., Inc. for the previous quarter, Wall Street now forecasts -9.52% negative EPS growth.

Since October 26, 2017, it had 0 insider purchases, and 4 insider sales for $810,133 activity. On Friday, March 16 Kenney Donald P sold $54,016 worth of Franklin Electric Co., Inc. (NASDAQ:FELE) or 1,280 shares. $435,937 worth of Franklin Electric Co., Inc. (NASDAQ:FELE) was sold by davis delancey w.

Franklin Electric Co., Inc. (NASDAQ:FELE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>